Stock was crushed today! Down 10%

Quote

anonymous

Guest
So much for another dismal earnings report! The shorts continue to win big. It's all over folks. Sheldon has run another company into the ground. Sales again were weak. Only 10,000 patients have been put on this drug since 2020. Let that sink in !! Nothing has gone right since launch. The stock has been diluated too many times as even Anthony is having a hard time being positive. If Jeaus was running this company it still wouldn't be profitable until 2027!
 






Today was awful and truly tells us bankruptcy is not far off. Nobody will buy us with our debt load we carry. The label change won't help either. Too hard to prescribe and get approved.
 






anonymous said:
So much for another dismal earnings report! The shorts continue to win big. It's all over folks. Sheldon has run another company into the ground. Sales again were weak. Only 10,000 patients have been put on this drug since 2020. Let that sink in !! Nothing has gone right since launch. The stock has been diluated too many times as even Anthony is having a hard time being positive. If Jeaus was running this company it still wouldn't be profitable until 2027!
Click to expand...

Not to mention the chemical patient expires in December 2025.
 






anonymous said:
So much for another dismal earnings report! The shorts continue to win big. It's all over folks. Sheldon has run another company into the ground. Sales again were weak. Only 10,000 patients have been put on this drug since 2020. Let that sink in !! Nothing has gone right since launch. The stock has been diluated too many times as even Anthony is having a hard time being positive. If Jeaus was running this company it still wouldn't be profitable until 2027!
Click to expand...



Who’s Jeaus? LMAO!
 






























The people I talk to are pretty bullish on the situation given the fact that debt is now under control and sales are really picking up. The label change coupled with all the insurance improvements will make for a very interesting 12 to 18 months; the reality is there likely will be a buyout sooner than later.
 






anonymous said:
The people I talk to are pretty bullish on the situation given the fact that debt is now under control and sales are really picking up. The label change coupled with all the insurance improvements will make for a very interesting 12 to 18 months; the reality is there likely will be a buyout sooner than late
Click to expand...
3rd Qtr results should tell us a lot about the trajectory in sales.. Once we see them and the results beat analyst expectations then, yes, i would agree with you on a buyout….
 






anonymous said:
3rd Qtr results should tell us a lot about the trajectory in sales.. Once we see them and the results beat analyst expectations then, yes, i would agree with you on a buyout….
Click to expand...
This is true and I think Merck is the most likely buyer; they need back in the cardio space and this were evanescence function as a space holder, and also generate a few dollars in preparation for their big launch.
 






anonymous said:
The people I talk to are pretty bullish on the situation given the fact that debt is now under control and sales are really picking up. The label change coupled with all the insurance improvements will make for a very interesting 12 to 18 months; the reality is there likely will be a buyout sooner than later.
Click to expand...
Who is the pumper here !
What a bunch of nonsense.
Someone has been posting " hope " posts that never arrive.
Get a life. And get some facts to any clinical discussion of benefits of BA.
 


















Stock looks solid, obviously a very rough day in the market, but we hold our own. People are beginning to clamor towards less speculative investments, and this bodes well for stocks like ESPR that are thoroughly washed out and offer significant upside potential. Look for a big bounce after earnings as the analysts scramble.
 






anonymous said:
Stock looks solid, obviously a very rough day in the market, but we hold our own. People are beginning to clamor towards less speculative investments, and this bodes well for stocks like ESPR that are thoroughly washed out and offer significant upside potential. Look for a big bounce after earnings as the analysts scramble.
Click to expand...
The word " clamor " again.
ESPR washed out is accurate.
What a post of nonsense.
 






























Top Bottom
Back
Quote